Chief of BioNTech: Very likely, our vaccine will work on the new version of the virus.

Chief executive of the German pharmaceutical company BioNTech has said he is confident that the coronary vaccine will operate against the new version shown in Britain, but that further studies are needed to say that for sure. Ugur Sahin said at a media conference that his team worked for them [...]
Ugur Sahin said at a media conference that his team worked to find out whether the vaccine they discovered would work on the variants of the choreography shown in Britain, or if it had to adapt. The results will become known within two weeks.
We don't know at the moment if our vaccine is likely to provide protection against this new version,” said Sahin, a day after the vaccine was approved for use in the European Union, the Guardian, translates Periscopi.
But, scientifically, it's very possible that the immune response from this vaccine can also deal with new versions of the virus. ” he added.
Sahin said that the version discovered in Britain had nine mutations, not just one, as was common.
However, he argued that proteins in this version were 99% the same as those in existing variants.
The other good news is that if he had to adjust the vaccine, Sahin said it would take only six weeks. /Periscope











